Clinical Trial Update: Defibrotide in COVID-19 Pneumonia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating defibrotide in patients with COVID-19 pneumonia completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia

Drugs mentioned

• Defibrotide (defibrotide)

Snippet

Sponsor: IRCCS San Raffaele | Conditions: Patients With COVID-19 Pneumonia Will Allow to Detect an Absolute Reduction in the Rate of Respiratory-failure | Phase 2 | Status: COMPLETED